PepGen (PEPG) Gains from Investment Securities (2021 - 2022)

PepGen (PEPG) posted Gains from Investment Securities of -$58000.0 for Q1 2022, up 6.45% sequentially from -$62000.0 in Q4 2021.

Analysis

PepGen (PEPG) Gains from Investment Securities (2021 - 2022) Analysis & Trends

PepGen has reported Gains from Investment Securities for 2 years, with the latest figure at -$58000.0 in Q1 2022.

Quarterly Gains from Investment Securities changed N/A year-over-year to -$58000.0 in Q1 2022, while the trailing twelve-month figure through Dec 2022 was -$58000.0 (changed N/A YoY) and the FY2022 annual result came in at -$58000.0, down 129.59% from the prior year.
Gains from Investment Securities improved to -$58000.0 in Q1 2022 per PEPG's latest filing, from -$62000.0 in the prior quarter.
Over five years, Gains from Investment Securities peaked at $65000.0 in Q3 2021 and troughed at -$62000.0 in Q4 2021.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	PepGen	217.99 Mn	217.99 Mn	-

Historic Data

Download Data